image credit: Bamboo Works
Key Takeaways:
The company's revenue stream amounts to a mere trickle for now, as its specialized instruments are only starting to be commercialized at scale
True Health is highly dependent on a single customer that has consistently contributed nearly 90% of revenue
The surgical robot changed how operations are carried out. Now a Chinese medical technology company wants to revolutionize the way needles are inserted to conduct biopsies or excise tumor tissue.
Guangdong True Health Medical Technology Development Co. Ltd. recently filed for a Hong Kong listing, seeking to raise money to develop and promote its range of robotic puncture tools.
While companies such as MicroPort MedBot (2252.HK) and Cornerstone Robotics focus on laparoscopic surgery, True Health has chosen a less-traveled path, using robotic systems to assist with micro incisions that require pinpoint accuracy. While the market is far smaller than for surgical systems, it could expand into a significant niche within China's medical robotics industry.
True Health was founded in 2018 by an entrepreneur with experience in medical imaging and precision treatment. Zhang Haoren chose to specialize in the emerging field of percutaneous puncture, primarily used to diagnose and treat lung, liver, and kidney cancers, to help physicians avoid errors in accessing hard-to-reach lesions.
In 2023 the company moved its headquarters from Beijing to Hengqin, Guangdong, where it is closely aligned with the province's plans to develop its healthcare industry. True Health's TH-X MW microwave ablation robot subsequently became the first innovative medical device to ...
